» Articles » PMID: 26884084

Estrogen Promotes Fat Mass and Obesity-associated Protein Nuclear Localization and Enhances Endometrial Cancer Cell Proliferation Via the MTOR Signaling Pathway

Overview
Journal Oncol Rep
Specialty Oncology
Date 2016 Feb 18
PMID 26884084
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive exposure to estrogen is generally acknowledged as a risk factor for endometrial cancer. Given that the accumulation of adipocytes also contributes to the increased production of estrogen, in the present study, we evaluated the expression of the fat mass and obesity-associated (FTO) gene in endometrial tumor tissues and further explored the mechanism of how estrogen facilitates FTO nuclear localization and promotes endometrial cancer cell proliferation. Immunohistochemical (IHC) staining assay was used to detect the FTO expression in endometrial tumor samples. Western blotting was performed to investigate the mechanism of estrogen-induced FTO nuclear localization. siRNA was used to knock down ERα and further explore its role in FTO nuclear localization. MTT assay was carried out to determine cell proliferation. We found that FTO was overexpressed in endometrial carcinoma tissues and served as a poor prognostic marker. Additionally, estrogen induced FTO nuclear accumulation via the mTOR signaling pathway and the nuclear localization was ERα-dependent, which contributed to enhanced proliferative activity. Therefore, the present study provides new insight into the mechanisms of estrogen-induced proliferation, implying the possibility of using FTO as a potential therapeutic target for the treatment of endometrial cancer.

Citing Articles

mTOR Pathway Inhibition, Anticancer Activity and In Silico Calculations of Novel Hydrazone Derivatives in Two- and Three-Dimensional Cultured Type 1 Endometrial Cancer Cells.

Bulbul M, Mermer A, Kolbasi B, Kocabas F, Kalender S, Kirectepe Aydin K Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770404 PMC: 11678851. DOI: 10.3390/ph17121562.


Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.

Alberti-Valls M, Olave S, Olomi A, Macia A, Eritja N Cancers (Basel). 2024; 16(23).

PMID: 39682106 PMC: 11640124. DOI: 10.3390/cancers16233918.


Epitranscriptomics and cervical cancer: the emerging role of mA, mC and mA RNA modifications.

Modi A, Zahid H, Southerland A, Modi D Expert Rev Mol Med. 2024; 26:e20.

PMID: 39377535 PMC: 11488341. DOI: 10.1017/erm.2024.20.


Meta-analysis of FTO expression on the clinicopathologic characteristics and prognosis of gastric cancer.

Zhu C, Da M, Wu Z, Ma J, Zhu C, An X Medicine (Baltimore). 2024; 103(39):e35714.

PMID: 39331892 PMC: 11441928. DOI: 10.1097/MD.0000000000035714.


Research progress on m6A demethylase FTO and its role in gynecological tumors.

Wang S, Liu Q Front Oncol. 2024; 14:1413505.

PMID: 39175477 PMC: 11338917. DOI: 10.3389/fonc.2024.1413505.